Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors

A macrocyclic compound having the structure of Formula (A) or a pharmaceutically acceptable salt thereof:

• wherein:
• R1 and R2 are phenyl independently optionally substituted by 1, 2, 3, or 4 substituents, as permitted;
• Z1 and Z2 are, independently, —SO—, —SO2—, —S(═O)N(R6)—, —S(═O)C(R7)(R6), —S(═O)2N(R6)—, —S(═O)2C(R7)(R6)—, —C(═O)—, —C(═O)N(R6)—, —C(═O)C(R7)(R6), —C(S)C(R7)(R6)— or —C(S)N(R6)—;
• R6 and R7 are, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteroaralkyl is optionally substituted with a substituent;
• v is an integer which is 1 or 0;
• T is —CH2—, —NH—, —S—, or —O—;
• L is an aliphatic chain having at least two contiguous carbon atoms, wherein L is interrupted by one or more —O—, —S—, —N(Rg)—,
• each Rg is, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, is optionally substituted by one or more suitable substituents;
• L-(T)v is a chain having at most 25 atoms in length;
• and
• each R3, R4 and R5 is, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, aralkyl, or heteroaralkyl is optionally substituted by one or more suitable substituent.